Cutia Therapeutics (HKG:2487)

Market Cap	1.87B +47.6%
Revenue (ttm)	274.31M +25.9%
Net Income	-517.51M
EPS	-1.65
Shares Out	363.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,200
Average Volume	300,564
Open	5.11
Previous Close	5.04
Day's Range	5.03 - 5.24
52-Week Range	3.64 - 12.84
Beta	0.87
RSI	54.08
Earnings Date	Nov 28, 2025

About Cutia Therapeutics

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication. The company’s products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 298
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2487

Financial Performance

In 2024, Cutia Therapeutics's revenue was 279.62 million, an increase of 103.17% compared to the previous year's 137.62 million. Losses were -433.81 million, -77.91% less than in 2023.

Financial numbers in CNY